LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

Search

Novo Nordisk A-S

Closed

SectorHealthcare

55.6 -0.82

Overview

Share price change

24h

Current

Min

55.36

Max

55.62

Key metrics

By Trading Economics

Income

-2.5B

27B

Sales

-1.2B

77B

P/E

Sector Avg

15.409

35.69

EPS

6.53

Dividend yield

2.84

Profit margin

34.484

Employees

78,387

EBITDA

-2.5B

44B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.79% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.84%

3.08%

Market Stats

By TradingEconomics

Market Cap

52B

268B

Previous open

56.42

Previous close

55.6

News Sentiment

By Acuity

74%

26%

341 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Novo Nordisk A-S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 sie 2025, 13:52 UTC

Major Market Movers

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 sie 2025, 09:23 UTC

Major Market Movers

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 sie 2025, 09:23 UTC

Major Market Movers

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 sie 2025, 06:52 UTC

Earnings

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 sie 2025, 06:21 UTC

Earnings

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

22 wrz 2025, 13:43 UTC

Acquisitions, Mergers, Takeovers

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 wrz 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18 wrz 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 wrz 2025, 08:55 UTC

Hot Stocks

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11 wrz 2025, 10:59 UTC

Market Talk

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10 wrz 2025, 13:24 UTC

Earnings

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10 wrz 2025, 09:16 UTC

Hot Stocks

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2 wrz 2025, 09:14 UTC

Hot Stocks

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21 sie 2025, 08:49 UTC

Earnings
Hot Stocks

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 sie 2025, 09:23 UTC

Hot Stocks

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 sie 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 sie 2025, 11:32 UTC

Earnings

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 sie 2025, 11:03 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 sie 2025, 10:41 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 sie 2025, 20:34 UTC

Earnings

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 sie 2025, 08:45 UTC

Earnings

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 sie 2025, 07:19 UTC

Market Talk
Earnings

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 sie 2025, 05:50 UTC

Earnings

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 sie 2025, 05:48 UTC

Earnings

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 sie 2025, 05:46 UTC

Earnings

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 sie 2025, 05:38 UTC

Earnings

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 sie 2025, 05:37 UTC

Earnings

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 sie 2025, 05:36 UTC

Earnings

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 sie 2025, 05:35 UTC

Earnings

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 sie 2025, 05:34 UTC

Earnings

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

7.79% upside

12 Months Forecast

Average 59.94 USD  7.79%

High 70 USD

Low 50 USD

Based on 8 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

62.63 / 69.23Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

341 / 371 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat